Results 11 to 20 of about 812,191 (301)
Pharmacologic Control of CAR T Cells [PDF]
International Journal of Molecular Sciences, 2021 Chimeric antigen receptor (CAR) therapy is a promising modality for the treatment of advanced cancers that are otherwise incurable. During the last decade, different centers worldwide have tested the anti-CD19 CAR T cells and shown clinical benefits in the treatment of B cell tumors.
Benjamin Caulier +2 more
openaire +4 more sources
Mathematical deconvolution of CAR T-cell proliferation and exhaustion from real-time killing assay data. [PDF]
, 2020 Chimeric antigen receptor (CAR) T-cell therapy has shown promise in the treatment of haematological cancers and is currently being investigated for solid tumours, including high-grade glioma brain tumours.
Abler, Daniel +13 more
core +2 more sources
Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy [PDF]
, 2020 Chimeric antigen receptor (CAR) T-cell therapy has produced remarkable anti-tumor responses in patients with B-cell malignancies. However, clonal kinetics and transcriptional programs that regulate the fate of CAR-T cells after infusion remain poorly ...
Adair, Jennifer E. +16 more
core +1 more source
International Journal of Molecular Sciences, 2020 CAR-T therapy has revolutionized the treatment of select hematological malignancies, namely, acute lymphoblastic leukemia and large B-cell lymphomas [...]
openaire +2 more sources
Biomarker Research, 2017 Chimeric antigen receptor redirected T cells (CAR-T cells) have achieved inspiring outcomes in patients with B cell malignancies, and are now being investigated in other hematologic malignancies and solid tumors. CAR-T cells are generated by the T cells from patients' or donors' blood.
Cheng Zhang +3 more
openaire +3 more sources
T Cell Maturation Stage Prior to and During GMP Processing Informs on CAR T Cell Expansion in Patients [PDF]
, 2016 textabstractAutologous T cells were genetically modified to express a chimeric antigen receptor (CAR) directed toward carboxy-anhydrase-IX (CAIX) and used to treat patients with CAIX-positive metastatic renal cell carcinoma.
Cor H. J. Lamers +4 more
core +9 more sources
Cells, 2022 The manufacture of efficacious CAR T cells represents a major challenge in cellular therapy. An important aspect of their quality concerns energy production and consumption, known as metabolism. T cells tend to adopt diverse metabolic profiles depending on their differentiation state and their stimulation level.
Christopher Forcados +4 more
openaire +4 more sources
CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing [PDF]
, 2019 BACKGROUND: Chimeric antigen receptor (CAR)-based T cell therapy is in early clinical trials to target the neuroectodermal tumor, neuroblastoma. No preclinical or clinical efficacy data are available for retinoblastoma to date.
Andersch, Lena +15 more
core +2 more sources
Turkish Journal of Hematology, 2023 Cytokine-release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are significant complications in patients with relapsed/refractory diffuse large B-cell lymphoma undergoing chimeric antigen receptor T-cell (CAR-T cell ...
Christian Messerli +9 more
doaj +1 more source